$809 Million is the total value of Boxer Capital, LLC's 24 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 60.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $55,200,000 | -9.5% | 1,200,000 | -12.7% | 6.82% | +0.7% |
| KNSA | Sell | KINIKSA PHARMACEUTICALS LTD | $8,162,000 | -72.7% | 290,577 | -75.2% | 1.01% | -69.6% |
| MDCO | Sell | MEDICINES CO | $4,440,000 | -89.4% | 232,000 | -83.4% | 0.55% | -88.2% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $2,805,000 | -91.4% | 50,000 | -87.5% | 0.35% | -90.4% |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.09% | – |
| BLPH | Exit | BELLEROPHON THERAPEUTICS INC | $0 | – | -1,482,143 | -100.0% | -0.18% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -0.44% | – |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -1,697,802 | -100.0% | -0.45% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -2,125,000 | -100.0% | -0.47% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -2,321,900 | -100.0% | -0.83% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BEIGENE LTD | 34 | Q2 2024 | 15.6% |
| MIRATI THERAPEUTICS INC | 33 | Q4 2023 | 55.2% |
| ROCKET PHARMACEUTICALS INC | 26 | Q2 2024 | 5.4% |
| KURA ONCOLOGY INC. | 26 | Q2 2024 | 4.7% |
| DBV TECHNOLOGIES S A | 26 | Q2 2024 | 3.9% |
| IDEAYA BIOSCIENCES INC | 21 | Q2 2024 | 4.8% |
| AKERO THERAPEUTICS INC | 21 | Q2 2024 | 4.5% |
| MILESTONE PHARMACEUTICALS INC | 21 | Q2 2024 | 2.6% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SPRINGWORKS THERAPEUTICS INC | 20 | Q2 2024 | 8.3% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Century Therapeutics, Inc. | April 22, 2024 | 4,901,603 | 5.8% |
| PMV Pharmaceuticals, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| FATE THERAPEUTICS INC | February 12, 2024 | 6,171,000 | 6.3% |
| Mirati Therapeutics, Inc. | January 25, 2024 | ? | ? |
| Nkarta, Inc. | January 18, 2024 | 4,407,350 | 9.0% |
| Rain Oncology Inc. | December 18, 2023 | 2,933,152 | 9.9% |
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-10-15 |
| SC 13D/A | 2024-10-15 |
| SC 13D/A | 2024-10-15 |
| SC 13G | 2024-09-27 |
| N-PX | 2024-08-28 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-07-18 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-14 |
| SC 13D/A | 2024-05-14 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.